Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

首席执行官

Mr. Daniel Marcel Legault J.D., L.L.B.

员工

国家

加拿大

ISIN

CA0370255097

上市

STU

4B70.STU

0 Comments

分享你的想法

FAQ

Antibe Therapeutics 今天的股价是多少？▼

4B70.STU 当前价格为 €2.44 EUR，在过去 24 小时内下跌了 -0%。在图表上更密切关注 Antibe Therapeutics 股票的表现。

Antibe Therapeutics 的股票代码是什么？▼

根据交易所不同，股票代码可能会有所不同。例如，在交易所，Antibe Therapeutics 的股票以代码 4B70.STU 进行交易。

Antibe Therapeutics 的股价在上涨吗？▼

4B70.STU 股票较上周上涨 +0%，本月上涨 +0%，过去一年 Antibe Therapeutics 上涨 +0%。

Antibe Therapeutics 有多少名员工？▼

截至五月 06, 2026，公司共有11名员工。

Antibe Therapeutics 属于哪个行业？▼

Antibe Therapeutics从事于健康与养生行业。

Antibe Therapeutics 何时完成拆股？▼

Antibe Therapeutics 最近没有进行任何拆股。

Antibe Therapeutics 的总部在哪里？▼

Antibe Therapeutics 的总部位于加拿大的 Toronto。